HealthDay News — For patients with type 2 diabetes (T2D), glycemic control is similar with use of regular human insulin (RHI) and rapid-acting insulin (RAI) when delivered with a wearable insulin delivery device, V-Go, according to a study presented at the virtual meeting of The Endocrine Society, held from March 28 to 31.
Pablo Mora, M.D., from the Dallas Diabetes Research Center, and colleagues conducted a noninferiority study in a population with T2D to compare the efficacy and safety of RAI versus RHI when delivered by V-Go. Data were assessed from 113 patients, including 59 with RHI and 54 with RAI.
The researchers found that the mean change in hemoglobin A1c was −0.60 percent from a baseline of 8.41 percent with RHI versus −0.38 percent from a baseline of 8.33 percent with RAI (estimated treatment difference [ETD], −0.22 percent; 95 percent confidence interval, −0.67 to 0.22 percent; noninferiority margin < 0.4 percent and P = 0.007). The mean change in total daily dose was 0.8 U/day from a baseline of 61.0 U/day with RHI versus 1.8 U/day from a baseline of 61.3 U/day with RAI (ETD, −1.04 U/day; 95 percent confidence interval, −3.18 to 1.11 U/day; P = 0.92). From prerandomization to postrandomization, the absolute change in percent of patients reporting hypoglycemia was +5.08 and +5.56 percent with RHI and RAI, respectively (ETD, −0.48 percent; 95 percent confidence interval, −10.6 to 9.1 percent; P = 0.91).
“Use of RHI with V-Go expands the affordability of insulin therapy,” a coauthor said in a statement.
One author disclosed financial ties to Valeritas, the manufacturer the V-Go device.